Connecting Sleep Disorder Diagnosis to Therapy

Supporting sleep professionals in the testing, diagnosis, and therapeutic monitoring of sleep disorders.

AI to Address the 80% Undiagnosed OSA Population

We are focused on the estimated 54 million Americans and 425 million patients globally¹ who suffer from sleep apnea, aiming to reach the 80% who are undiagnosed².

Our FDA-cleared SaMDs, EnsoSleep PPG and EnsoSleep, support clinicians seamlessly across a patient’s sleep journey, connecting sleep disorder diagnosis to therapy.

EnsoSleep PPG - no pineapple

FDA-Cleared, AI-Powered Sleep Diagnosis Using Pulse Oximeters

  • 8+ physiological signals, including photoplethysmogram (PPG), SpO2, pulse, snore, acoustic flow, position, HRV, actigraphy, and surrogate effort

  • Comfortable ring and watch form factors

  • Up to 7 nights of testing reduces night-to-night variability

EnsoSleep PPG Compatible Devices include FDA-cleared rings, watches, and duckbills

AI Scoring and Sleep Study Management for PSGs and HSATs

  • AI scoring use results in an average 62% time savings on PSGs and an average 68% time savings on HSATs

  • Cloud-based study management platform expedites clinical actions across all devices, locations, and teams

  • 93% Overall AHI Agreement, 94% SDB Agreement, 86% Sleep Staging Agreement, 98% CSA Agreement

Celeste+ is the FDA-cleared mobile application used with EnsoSleep PPG to collect and transfer data from pulse oximeters. EnsoSleep PPG analyzes the data and displays the results in EnsoSleep PPG Study Management for viewing and editing sleep studies and finalizing the diagnostic report.

Celeste+ Workflow Graphic

EnsoSleep PPG-enabled Remote Physiological Monitoring (RPM)

  • Seamlessly monitor patient success and titrate remotely on CPAP, GLP-1s, HGNS, and oral appliances

  • Cloud-based access to patient therapy data expedites clinical actions and improves patient outcomes

“EnsoData’s RPM solution uses the same device for monitoring therapy as for testing, making it very user friendly for both patients and our team.”

“Our patients already understand the devices and the app from testing, so there’s no learning curve.”

Ernesto Eusebio, MD, Sleep & Apnea Institute of Florida

500+

US Sleep Centers

Wondering about the pineapple?

Connect with Us to Learn How to Optimize the Sleep Lab Workflow from Testing through Treatment

Discover how EnsoData’s suite of AI solutions are designed to simplify and accelerate the sleep testing, diagnosis, and treatment workflow, providing sleep teams with more opportunities to expand patient care, improve outcomes, reach more patients, and impact sleep center growth.

Simply fill out our form and a team member will reach out to schedule an online consultative meeting and demo.

1: Benjafield, A. V., Ayas, N. T., Eastwood, P. R., et. al. (2019). Estimation of the global prevalence and burden of obstructive sleep apnoea: A literature-based analysis. The Lancet Respiratory Medicine, 7(8), 687–698. https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(19)30198-5/abstract
2: Terry Young, Linda Evans, Laurel Finn, Mari Palta, Estimation of the Clinically Diagnosed Proportion of Sleep Apnea Syndrome in Middle-aged Men and Women, Sleep, Volume 20, Issue 9, September 1997, Pages 705–706, https://doi.org/10.1093/sleep/20.9.705